The feasibility of low dose CT combined with serum tumor markers in the early diagnosis of lung cancer at high risk of lung cancer
-
摘要:
目的探讨肺癌高危人群中低剂量CT(LDCT)联合血清肿瘤标志物对肺癌早期诊断的可行性。 方法筛选1020例来我院进行体检的肺癌高危人群，按照随机数字法分为两组：LDCT+血清肿瘤标志物组420例与CXR组600例。比较两组检查 结果。 结果（1）本次研究进行CXR检查的600例患者中，12例（2.0%）存在多个非钙化的结节情况；给予相关检查后，2例确诊为该种癌症，所占比重为0.33%；本组420例受检者之中，56例（占13.33%）经LDCT检查发现存在不同个数的非钙化结节，显著高于CXR组（P＜0.01）；（2）对比3组血清标志物水平，CEA水平在3组之间存在显著性差异（P＜0.01）。结论LDCT联合血清肿瘤标志物对肺癌早期诊断可行性较高，且临床价值高。 Abstract:Objective To investigate the feasibility of low dose CT (LDCT) combined with serum tumor markers in lung cancer at high risk for early diagnosis of lung cancer. Methods A total of 1020 patients with lung cancer in our hospital were divided into 2 groups according to the random number method: 420 cases of LDCT+ serum tumor marker group and 600 cases of CXR group. Comparison of two groups of inspection results. Results (1) In the group that 600 cases examined by CXR, 12 cases (2%) were found to have different numbers of non calcified nodules. The CXR, final diagnosed with lung cancer in 2 cases (0.33%); in the group with 420 subjects, 56 patients (13.33%) found that there is a different number of non calcified nodules by LDCT, significantly higher than that of CXR group (P＜0.01); (2) LDCT+ serum tumor signs in groups, diagnosed lung cancer group (n=5), screening positive group (n=56) and screening negative group (n=359) three groups of serum tumor markers compared to CEA levels between the three groups there was significant difference (P＜0.01). Conclusion LDCT combined with serum tumor markers in lung cancer high-risk population is feasible in the early diagnosis of lung cancer, and the clinical value is high. -
Key words:
- low dose CT /
- lung cancer high risk population /
- early diagnosis
-
表 1 LDCT+肿瘤标志物组各组间CEA、CA125及CA199水平比较（x±s）
肿瘤标志物 确诊肺癌组（n=5） 筛选阳性组（n=56） 筛选阴性组（n=359） CEA（ng/mL） 28.69±7.93 2.45±0.37* 2.50±0.52* CA125（U/mL） 7.81±0.82 8.28±0.56 10.28±0.67 CA199（U/mL） 9.71±0.92 9.30±0.87 8.86±0.75 *P ＜0.01 vs 确诊肺癌组 
下载: 导出CSV
-
[1] 李毅星. 血清肿瘤标记物联合检测在肺癌诊断中的应用价值[J]. 中国煤炭工业医学杂志, 2011, 14(1): 72-3. [2] 邓晶晶, 汪小鹏, 吴开松. 联合检测肿瘤标志物对肺癌的诊断价值[J]. 咸宁学院学报:医学版, 2011, 25(2): 115-7. [3] 廖君群. 胸腔积液CEA、CA19-9、CYFRA21-1、AFP和FERR在肺癌诊断中的价值[J]. 国际检验医学杂志, 2013, 34(10): 1216-8. [4] 孟丽娟, 王峻, 王友, 等. 低剂量CT联合血清P16甲基化检测在肺癌早期诊断中的研究[J]. 实用老年医学, 2007, 21(2): 118-20. [5] National Lung Screening Trial Research Team, Abede DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409. [6] 阎飞, 张定昌. 血清肿瘤标记物联合检测诊断肺癌的临床价值[J]. 山东医药, 2011, 51(19): 67-8. [7] Jemal A, Bray F, Center MM, et al. Global Cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. [8] 李海燕, 刘红, 王静, 等. 肿瘤标志物联合检测在肺癌诊断中的价值 [J]. 中国老年学杂志, 2012, 32(1): 46-8. [9] 黄刚, 移康, 李生虎, 等. 低剂量CT肺结节体积测量的实验研究[J]. 医学影像学杂志, 2013, 23(10): 1639-41, 1644. [10] 张宝秋, 丁湘彧, 王雪玉, 等. 肿瘤标志物联合检测在肺癌诊断中的应用价值[J]. 国际检验医学杂志, 2012, 33(4): 388-90. [11] 徐恩赐, 王利利, 周菊英. 联合检测血清CEA、CYFRA21-1、NSE在肺癌诊断、分期、分型中的意义[J]. 中国血液流变学杂志, 2012, 22(2): 270-3, 279. [12] 苏士成, 蔡敏, 屠建春, 等. 低剂量CT联合血清肿瘤标志物对肺癌早期筛查的价值[J]. 山东医药, 2012, 52(33): 49-50. [13] 张勇, 洪群英, 施伟斌, 等. 低剂量螺旋CT在肺癌筛查中的应用价值 [J]. 中华医学杂志, 2013, 93(38): 3011-4. [14] 洪群英, 张勇, 白春学. 肺癌筛查和早期诊断的现状[J]. 国际呼吸杂志, 2013, 33(24): 1888-91. [15] 王建卫, 吴宁, 唐威, 等. 低剂量CT肺癌筛查检出肺癌的影像特征[J]. 中华放射学杂志, 2015, 49(5): 336-9. -
点击查看大图
表(1)
计量
- 文章访问数: 506
- HTML全文浏览量: 189
- PDF下载量: 2
- 被引次数: 0
